AI Portfolio Summary
In 2016 Q2, Flagship Ventures Fund IV General Partner LLC maintained a portfolio of 5 distinct positions. The most significant new addition to the portfolio was EDITAS MEDICINE INC, which now represents 20.67% of the total fund value. The fund also reduced its exposure to SERES THERAPEUTICS I by 9.9%.
Total Positions
5
Quarter
2016 Q2
Top Holding
N/A (63.0%)
Top 10 Concentration
100.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-5 of 5
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
N/A
SERES THERAPEUT...
|
—
|
Unknown | 62.99% | 97.53% |
#1
Prev: #1
|
6.5 | -1,400,703 | -9.9% |
P
S
|
12,682,876 | $368,438,000 | — | 13F Filing | 2016-06-30 | 2016-08-14 (Est.) | ||
|
EDIT
EDITAS MEDICINE...
|
Healthcare | 20.67% | — |
#2
Prev: #—
|
9.0 | 4,955,316 | no change |
NEW
|
4,955,316 | $120,910,000 | 2016 Q2 | 13F Filing | 2016-06-30 | 2016-08-14 (Est.) | |||
|
SYRS
SYROS PHARMACEU...
|
Healthcare | 14.92% | — |
#3
Prev: #—
|
8.5 | 4,806,656 | no change |
NEW
|
4,806,656 | $87,241,000 | 2016 Q2 | 13F Filing | 2016-06-30 | 2016-08-14 (Est.) | |||
|
N/A
T2 BIOSYSTEMS I...
|
—
|
Unknown | 1.00% | 1.60% |
#4
2
Prev: #2
|
1.9 | no change | no change |
P
S
|
741,755 | $5,852,000 | — | 13F Filing | 2016-06-30 | 2016-08-14 (Est.) | ||
|
N/A
ELEVEN BIOTHERA...
|
—
|
Unknown | 0.42% | 0.87% |
#5
2
Prev: #3
|
1.7 | no change | no change |
P
S
|
1,466,417 | $2,464,000 | — | 13F Filing | 2016-06-30 | 2016-08-14 (Est.) |
Showing 1-5 of 5 holdings